Literature DB >> 15894770

Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.

G Y H Lip1, L A Pearce, B S P Chin, D S G Conway, R G Hart.   

Abstract

OBJECTIVE: To examine further the relations of plasma von Willebrand factor (vWf, an index of endothelial damage and dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations to the presence and onset of clinical congestive heart failure (CHF) and the degree of left ventricular (LV) dysfunction in patients taking part in the SPAF (stroke prevention in atrial fibrillation) study.
METHODS: Plasma concentrations of vWf and sP-sel were measured by enzyme linked immunosorbent assay (ELISA) in 1321 participants in the SPAF III study and related to the presence and onset of clinical CHF, as well as echocardiographic findings. Of the 1321 patients with atrial fibrillation (AF), 331 (25%) had a documented history of clinical heart failure, of which 168 cases were related to a new or recurrent episode of acute decompensated heart failure occurring within the preceding three months.
RESULTS: Mean plasma vWf was higher among patients with AF and CHF (154 (29) v 144 (31) IU/dl, p < 0.001), particularly those with acute or recent decompensated symptoms. Patients with severe LV dysfunction on two dimensional echocardiography and low fractional shortening also had significantly higher vWf concentrations than those with no LV dysfunction. CHF patients with clinical features--with (156 (28) IU/dl) and without (152 (31) IU/dl) LV dysfunction--also had higher mean vWf concentrations than patients with asymptomatic LV dysfunction (146 (31) IU/dl, p < 0.001). The presence of mitral regurgitation in CHF was associated with lower vWf concentrations. Plasma sP-sel concentrations were not affected by presence, onset, or severity of heart failure.
CONCLUSIONS: CHF may contribute to hypercoagulability and thrombotic risk in AF through increased endothelial damage and dysfunction. Patients with acute or recent decompensated features have the highest degree of endothelial damage and dysfunction. The presence of CHF clinical features was an important determinant of plasma vWf concentrations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894770      PMCID: PMC1768962          DOI: 10.1136/hrt.2004.036160

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  32 in total

1.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

Review 2.  Does heart failure confer a hypercoagulable state? Virchow's triad revisited.

Authors:  G Y Lip; C R Gibbs
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

3.  Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.

Authors:  Dwayne S G Conway; Lesly A Pearce; Bernard S P Chin; Robert G Hart; Gregory Y H Lip
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

4.  A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.

Authors:  Carl van Walraven; Robert G Hart; George A Wells; Palle Petersen; Peter J Koudstaal; Annette L Gullov; Beppie S P Hellemons; Birgitte G Koefed; Andreas Laupacis
Journal:  Arch Intern Med       Date:  2003-04-28

5.  Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.

Authors:  C R Gibbs; A D Blann; R D Watson; G Y Lip
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

6.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Thomas J Wang; Joseph M Massaro; Daniel Levy; Ramachandran S Vasan; Philip A Wolf; Ralph B D'Agostino; Martin G Larson; William B Kannel; Emelia J Benjamin
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

7.  Increased embolic risk in patients with left ventricular thrombi.

Authors:  J R Stratton; A D Resnick
Journal:  Circulation       Date:  1987-05       Impact factor: 29.690

Review 8.  Lessons from the Stroke Prevention in Atrial Fibrillation trials.

Authors:  Robert G Hart; Jonathan L Halperin; Lesly A Pearce; David C Anderson; Richard A Kronmal; Ruth McBride; Elaine Nasco; David G Sherman; Robert L Talbert; John R Marler
Journal:  Ann Intern Med       Date:  2003-05-20       Impact factor: 25.391

9.  Flow characteristics in the dilated left ventricle with thrombus: qualitative and quantitative Doppler analysis.

Authors:  S S Maze; M N Kotler; W R Parry
Journal:  J Am Coll Cardiol       Date:  1989-03-15       Impact factor: 24.094

10.  Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.

Authors:  Dwayne S G Conway; Lesly A Pearce; Bernard S P Chin; Robert G Hart; Gregory Y H Lip
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

View more
  12 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 3.  Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.

Authors:  Christopher J Boos; Michael Nam; A J Camm
Journal:  Heart Fail Rev       Date:  2013-06-25       Impact factor: 4.214

4.  Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation.

Authors:  George I Varughese; Jeetesh V Patel; Joseph Tomson; Gregory Y H Lip
Journal:  Heart       Date:  2006-09-27       Impact factor: 5.994

5.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

6.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 7.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31

8.  Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study.

Authors:  David S Frankel; James B Meigs; Joseph M Massaro; Peter W F Wilson; Christopher J O'Donnell; Ralph B D'Agostino; Geoffrey H Tofler
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

Review 9.  Epidemiology, diagnosis, and management of atrial fibrillation in women.

Authors:  Daniela Poli; Emilia Antonucci
Journal:  Int J Womens Health       Date:  2015-06-11

10.  D-dimer level and long-term outcome in patients with end-stage heart failure secondary to idiopathic dilated cardiomyopathy.

Authors:  Bi Huang; Yuan-Jing Li; Jian Shen; Yuan Yang; Gang Liu; Su-Xin Luo
Journal:  J Geriatr Cardiol       Date:  2019-08       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.